PDCD1 and osteosarcoma: Fourth, heterogeneous PD-L1 expression among osteosarcoma patients further limits the uniform effectiveness of PD-1/PD-L1 blockade, as not all patients exhibit sufficient PD-L1 levels to benefit from this therapy (39).